Jia, W., Qin, S., Zhou, J., Sun, H., Huang, C., Zhiping, Y., Peng, T., Shi, X., Gu, S., Peng, L., Zha, Y., Zheng, J., Ren, H., Lin, K., Chen, Z., Liu, R., Liu, Z., Yang, J., Yang, Q., Fan, J. (2026). Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4001